Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) are two of the most common neurological diseases affecting elderly populations around the world. While both share similar symptoms of memory loss, impaired coordination, and motor dysfunction, there are several distinctions between Alzheimer’s disease and Parkinson’s disease. Alzheimer’s disease is a progressive form of dementia among the elderly characterized by memory loss, impaired thinking, difficulty communicating, and changes in personality and behavior. It is caused by a buildup of plaques and tangles in the brain, which impairs connections between neurons, and ultimately leads to neuron death. The cause of Alzheimer’s is still unknown, but researchers suspect that it is largely genetically determined. Parkinson’s disease is a degenerative disorder that significantly impairs movement, often leading to tremors, slower movements, and general muscle stiffness. Unlike Alzheimer’s, Parkinson’s disease is caused by the death of brain cells that produce dopamine, a neurotransmitter responsible for many of the body’s movements. This affects a specific area of the brain called the substantia nigra, which is responsible for controlling muscle coordination. The cause of Parkinson’s disease is also largely unknown, though environmental factors, such as exposure to toxins, have been linked to an increased risk of developing the disease. The primary difference between Alzheimer’s and Parkinson’s is the region of the brain that is affected. While Alzheimer’s affects regions of the brain responsible for memory and cognition, Parkinson’s causes the death of cells responsible for controlling muscle coordination.
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom